Patent · US Active

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

US11845989B2 · kind B2 · utility

0Cited by

21References

4Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Kavita Praveen · Tarrytown, US
Claudia Schurmann · Tarrytown, US
Lauren Gurski · Tarrytown, US
Tanya Teslovich Dostal · Tarrytown, US
Goncalo Abecasis · Tarrytown, US
Aris Baras · Tarrytown, US
Giovanni Coppola · Tarrytown, US
Gaurang Patel · Tarrytown, US
Ying Hu · Scarsdale, US
Carmelo Romano · Tarrytown, US
Giusy Della Gatta · Tarrytown, US
Trikaldarshi Persaud · Tarrytown, US

Key dates

Filing date	Sep 24, 2020
Grant date	Dec 19, 2023
Priority date	—
Expiry date	Oct 27, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/156
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.